Abstract: Embodiments of the present disclosure pertain to bioink compositions that are operational to form an artificial tissue. The bioink may include materials that are completely or primarily derived from humans, such as human tissues. Additional embodiments of the present disclosure pertain to artificial tissues that include a plurality of cells and a bioink of the present disclosure, where the bioink is embedded with the cells, and the artificial tissue is in the form of a three-dimensional structure. Further embodiments of the present disclosure pertain to methods of making the artificial tissues of the present disclosure by applying a plurality of cells and a bioink onto a surface.

Abstract: The present invention includes a method of inhibiting or reducing deregulated JAK tyrosine kinase activity or JAK/ STAT signaling in a subject with a disease by administering Moxidectin or derivatives thereof in an amount sufficient to treat the disease in a subject, a therapeutically or prophylactically effective amount of the compound of Formula I or pharmaceutically acceptable salt thereof.

Abstract: The present invention includes composition and methods for treating cancers comprising administering to a subject a pharmaceutical composition comprising Pimavanserin, active polymorphs, or salts thereof in an amount sufficient to treat the cancer in the subject and a pharmaceutically acceptable carrier.

Abstract: The present invention includes composition and methods for treating cancers comprising administering to a subject a pharmaceutical composition comprising Pimavanserin or derivatives thereof in an amount sufficient to treat the reproductive cancer in the subject and a pharmaceutically acceptable carrier.

Abstract: The present invention includes composition and methods for treating cancers comprising administering to a subject a pharmaceutical composition comprising Pimavanserin or derivatives thereof in an amount sufficient to treat the reproductive cancer in the subject and a pharmaceutically acceptable carrier.

Abstract: The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.

Abstract: The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.